Sort
48,018 grants matching “immunotherapy”
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC
$930,592Cathy A Swindlehurst · Novomedix, Inc. · R44 · FY2023 · HL
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy
$930,383Joshua Aiden Hill · Fred Hutchinson Cancer Center · R01 · FY2023 · CA
TRANSPLANT TOLERANCE
$930,249Emory University · U19 · FY2002 · AI
Role of Tumor Stroma in Therapeutic Response and Resistance
$930,118Lynda Chin · University Of Tx Md Anderson Can Ctr · U54 · FY2011 · CA
Microglia-Amyloid interactions in delirium superimposed on dementia
$930,072Niccolo Terrando · Duke University · R01 · FY2024 · AG
How Does blockade of CD40/CD40L Prevent Autoimmunity?
$930,029La Jolla Inst For Allergy &Immunolgy · U19 · FY2004 · AI
Human natural killer cells: Advancing biology and clinical applications
$930,000Michael A Caligiuri · Ohio State University · R35 · FY2017 · CA
Development of novel immunotherapy for influenza virus infection
$929,766Kazue Takahashi · Massachusetts General Hospital · U01 · FY2011 · AI
Targeting CNS reservoirs with CAR/CXCR5 T cells for the long-term remission of HIV
$929,754Pamela J Skinner · University Of Minnesota · R01 · FY2022 · MH
Discovery of solubilizing side chains for in vivo release of diverse drug classes using the Click Activated Protodrugs (CAP) platform
$929,651Nathan Yee · Tambo, Inc. · R44 · FY2024 · TR
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
$929,563William Laurence Dahut · Division Of Clinical Sciences - Nci · ZIA · FY2016 · CA
Human monoclonal antibody therapy for HUS
$929,151Feinstein Institute For Medical Research · UC1 · FY2004 · AI
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumors
$928,524Jeffrey S Miller · University Of Minnesota · R35 · FY2025 · CA
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumors
$928,524Jeffrey S Miller · University Of Minnesota · R35 · FY2023 · CA
Targeting PD-1 Pathway for Functional Cure of AIDS
$928,498Rama Rao Amara · Emory University · R01 · FY2024 · AI
A Cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses
$928,329Eric Bruening · Tomegavax, Inc. · R44 · FY2017 · CA
Study of CAR T cells and mechanisms of resistance in pediatric brain tumors
$928,184Anandani Nellan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Characterizing genomic risk factors of lung cancers in Native Hawaiians
$928,101Youping Deng · University Of Hawaii At Manoa · U54 · FY2023 · HG
Regulatory T cells and the tumor microenvironment
$927,924Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · R35 · FY2021 · CA
Vascular macrophages and T cells in atherosclerosis
$927,585Klaus F. Ley · La Jolla Institute For Immunology · R35 · FY2019 · HL
A systems approach to manipulate microbial adaptation to structured environments
$927,560Nitin S Baliga · Institute For Systems Biology · R01 · FY2019 · AI
EpCAM (CD326) Function in Epithelial Cell Biology and Immunophysiology
$927,509Mark Udey · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
A Randomized Controlled Trial to Evaluate the Safety
$927,493University Of Southern California · M01 · FY2004 · RR
Overcoming resistance to anti-PD1 immunotherapy
$927,149Thomas F Gajewski · University Of Chicago · R35 · FY2023 · CA
Preclinical Development of a Novel and Powerful Immunotherapeutic
$926,922Susan Dana Jones · Immurx Llc · R44 · FY2011 · AI